<DOC>
	<DOC>NCT01726439</DOC>
	<brief_summary>To compare the effectiveness, in a real world practice setting in tier 2 cities of China, of Entecavir (ETV) monotherapy and Lamivudine (LAM) based therapies (including LAM monotherapy, de novo LAM + Adefovir [ADV] combination, and early add-on of ADV) among chronic hepatitis B (CHB) patients who are naive to NUC at enrollment to this study</brief_summary>
	<brief_title>Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China</brief_title>
	<detailed_description>Sampling Method: Consecutive patient sampling Biospecimen Retention: Blood samples for HBV viral load testing along the treatment period of this study</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>CHB patients, or CHB patients with compensated cirrhosis, as defined by the current Chinese guidelines Male or female ≥ 18 years of age Either Hepatitis B e antigen (HBeAg) positive or negative Naïve to NUC (defined as no previous exposure to NUC treatment as based on patient selfreport) Has compensated liver disease Patients with compensated cirrhosis Patients who consent to participate in this study Local residents with medical reimbursement coverage preferred Coinfected with hepatitis C virus (HCV) CHB patients with decompensated cirrhosis, liver failure, hepatocellular carcinoma, or any other types of malignancy at the screening phase CHB patients who are being treated by interferon therapy within 6 months immediately prior to the screening phase of this study CHB patients with a confirmed pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>